This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PNT POINT Biopharma Global (PNT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About POINT Biopharma Global Stock (NASDAQ:PNT) 30 days 90 days 365 days Advanced Chart Get POINT Biopharma Global alerts:Sign Up Key Stats Today's Range N/A50-Day Range$12.45▼$14.2352-Week Range N/AVolume3.29 million shsAverage Volume1.44 million shsMarket Capitalization$1.33 billionP/E Ratio13.89Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana. Read More Receive PNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for POINT Biopharma Global and its competitors with MarketBeat's FREE daily newsletter. Email Address PNT Stock News HeadlinesProta Therapeutics Strengthens Board with Appointment of Global Biotech Expert Patrick MachadoJuly 24, 2024 | markets.businessinsider.comWhat's Going On With GT Biopharma Stock?May 20, 2024 | msn.com“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning. | InvestorPlace (Ad)Investing in biopharma innovation: Can you stay one step ahead?April 8, 2024 | bloomberg.comDomain Therapeutics Strengthens Leadership Team to Spearhead Global Development and North American Expansion as the Leading GPCR Immuno-Oncology CompanyJanuary 8, 2024 | businesswire.comLilly Completes Acquisition of POINT BiopharmaDecember 27, 2023 | finance.yahoo.comPOINT Biopharma Global Rating Adjustment: Hold Recommendation Following Shareholder Dynamics and Acquisition ProspectsDecember 22, 2023 | markets.businessinsider.comBrookline Capital Downgrades POINT Biopharma Global (PNT)December 22, 2023 | msn.comSee More Headlines PNT Stock Analysis - Frequently Asked Questions How were POINT Biopharma Global's earnings last quarter? POINT Biopharma Global Inc. (NASDAQ:PNT) released its quarterly earnings results on Monday, November, 13th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.07. The business had revenue of $2.79 million for the quarter, compared to analysts' expectations of $8 million. POINT Biopharma Global had a net margin of 39.62% and a trailing twelve-month return on equity of 21.10%. What other stocks do shareholders of POINT Biopharma Global own? Based on aggregate information from My MarketBeat watchlists, some other companies that POINT Biopharma Global investors own include NVIDIA (NVDA), Broadcom (AVGO), Novo Nordisk A/S (NVO), Disc Medicine (IRON), Arista Networks (ANET), e.l.f. Beauty (ELF) and Builders FirstSource (BLDR). Company Calendar Last Earnings11/13/2023Today8/25/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PNT CIK1811764 Webwww.pointbiopharma.com Phone64-7812-2417FaxN/AEmployees129Year FoundedN/AProfitability EPS (Trailing Twelve Months)$0.90 Trailing P/E Ratio13.89 Forward P/E RatioN/A P/E GrowthN/ANet Income$98.29 million Net Margins39.62% Pretax Margin52.16% Return on Equity21.10% Return on Assets18.28% Debt Debt-to-Equity Ratio0.01 Current Ratio9.14 Quick Ratio9.14 Sales & Book Value Annual Sales$226.58 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow13.31 Book Value$4.68 per share Price / BookN/AMiscellaneous Outstanding Shares106,570,000Free Float89,518,000Market Cap$1.33 billion OptionableOptionable BetaN/A The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:PNT) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBreaking News: Trump Could Unlock $21 Trillion for Everyday AmericansPresident Trump just signed a new law… That could unlock $21 trillion for everyday folks like you… And p...Brownstone Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding POINT Biopharma Global Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share POINT Biopharma Global With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.